TTLTicker Tales
NSE: APOLLOHOSPHealthcare

Apollo Hospitals Enterprise

Apollo Hospitals runs one of India's largest hospital chains along with a pharmacy network, diagnostics business and a digital health platform (Apollo 24/7).

₹8,446.00▲+8.8%1 yearClosing price, 6 Nov 2026
  • P/E ~54x
  • Digital arm turned cash-positive
  • Demerger of digital biz pending (Q4 FY27)
  • Promoter pledge cut 13%→~2.5%
  • Near 52-wk high

Updated on 7 Nov 2026 · Data as of 6 Nov 2026

Get this report as a PDF free, straight to your inbox.

Snapshot

Share price
₹8,446.00
6 Nov 2026
52-week range
₹6,776.60 – ₹9,069.00
All-time peak
₹9,069.00
23 Sept 2026 · −6.9% from peak
Dividend yield
0.24%
Price history since
2002
About 24 years of prices
52-week low ₹6,776.60high ₹9,069.00

What's happening

Q2 FY27 results (reported Nov 4, 2026) showed revenue up 23% YoY to ₹7,615 crore and PAT up 32% to ₹630 crore, with occupancy rising to 73% from 69%. Separately, the government's drug pricing regulator (NPPA) capped trade margins at 30% on 137 anti-cancer drug formulations effective November 9, 2026, which matters because oncology is roughly a fifth of revenue for large hospital chains. The long-planned demerger of the digital/pharmacy business (AHLL, Apollo 24/7 and Keimed) into a separately listed entity has NCLT and shareholder approval but is still pending, with management guiding to a listing in Q4 FY27 (Jan-Mar 2027) and no record date announced yet.

In plain terms

This is a hospital company bundled with a pharmacy chain, a diagnostics arm and a loss-making-turned-breakeven online health app, which makes it harder to value than a pure hospital business. The core hospital business is growing well on both patients treated and margins, which is the healthier kind of growth. But a chunk of the group (digital plus pharmacy distribution) is being carved out into a new company that isn't trading yet, so today's share price reflects a business that is about to change shape. On top of that, a fresh government cap on cancer-drug margins lands right after results, adding a near-term question mark on the pharmacy side.

Quarters

Revenue and profit have accelerated through FY27: Q1 FY27 revenue was up ~21% YoY with EBITDA margin at 15.5%, and Q2 FY27 revenue rose 23% YoY with EBITDA margin expanding further to 15.64% from 14.93% a year earlier, and PAT up 32% YoY. For H1 FY27 overall, revenue was up 22% and PAT up 33%. Importantly, the growth rode on both occupancy (73% vs 69%) and bed additions (+5.9% to 8,522 beds), not just pricing. The digital arm (Apollo 24/7) swung from a loss to a small cash profit, and AHLL's EBITDA margin rose to 14.3% from 9.5%, with AHLL posting a ₹26 crore profit versus a ₹4 crore loss a year ago - both are margin-led turnarounds within smaller segments rather than the core driver of group growth. Newer hospitals (Gurugram, Sonarpur, Financial District Hyderabad, Sarjapur) are still ramping and together dragged ~₹35 crore in losses this quarter.

Performance

Heads-up on splits: Apollo Hospitals Enterprise has split its shares or issued bonus shares before (most recently 2-for-1 on 2 Sept 2010). A sudden price drop around a split date is usually just the price adjusting for the extra shares, not a crash.

Share price

+8.8% over 1 year

Returns by period

PeriodApollo Hospitals EnterpriseNifty 50Max Healthcare Institute
3 months−5.5%+1.9%−12.7%
1 year+8.8%−1.9%−16.9%
3 years+65.7%+29.0%+57.1%
5 years+94.3%+38.5%+176.9%

₹100 invested on 8 Nov 2021 became…

  • Apollo Hospitals Enterprise₹194
  • Nifty 50₹139
  • Max Healthcare Institute₹277

The stock is down 6.9% from its September 23, 2026 peak but this is a mild pullback, not a crash - it remains well above its 52-week low of ₹6,776.6 and close to its 52-week high of ₹9,069. The only corporate action in the stock's history is a 2010 stock split (already reflected in prices), so none of the long-term return numbers need adjustment for spin-offs. Over 1 and 3 years the stock has beaten both the Nifty and peer Max Healthcare (1Y: +8.8% vs Nifty -1.88% and peer -16.86%; 3Y: +65.68% vs Nifty +28.98% and peer +57.06%). But over 5 years Apollo's +94.34% trails Max Healthcare's +176.94% by a wide margin, so the recent outperformance is a reversal of a longer period of lagging the peer.

Dividend

Paid in the last 12 months

₹20.00 per share

Dividend yield

0.24%

Dividend yield is the last 12 months of dividends divided by today's share price. A 0.2% yield means every ₹100 of Apollo Hospitals Enterprise shares paid about ₹0.2 in dividends over the past year. Past payouts can change.

Recent dividends

DatePer share
14 Aug 2026₹10.00
16 Feb 2026₹10.00
19 Aug 2025₹10.00
14 Feb 2025₹9.00
16 Aug 2024₹10.00
20 Feb 2024₹6.00
18 Aug 2023₹9.00
24 Feb 2023₹6.00

Valuation

Apollo trades at roughly 53-54x trailing earnings, cheaper than Max Healthcare (~71x) and Fortis (~64x) on that measure, but more expensive on price-to-book (~11.4x vs ~9.4x and ~6.6x respectively) - the two metrics disagree because Apollo's blended business (hospitals, pharmacy, diagnostics, digital) carries a different earnings mix than the peers' purer hospital models. Its EV/EBITDA of roughly 34x is actually about 30% below its own 3-year average of ~47x, suggesting the market has partly de-rated it, plausibly reflecting uncertainty around the pending demerger and the fresh oncology-drug margin cap rather than a view that the hospital business itself is cheap.

Growth

Growth is currently both volume-led and margin-led, which is the more durable combination: occupancy rose to 73% from 69% and operating beds grew 5.9%, while EBITDA margin simultaneously expanded to 15.64% from 14.93%. The digital and AHLL segments are improving mainly through margin expansion off a small base (AHLL margin 9.5% to 14.3%; digital arm loss to small cash profit) rather than large revenue gains, so their contribution to group growth is still modest in absolute rupee terms.

Health

EBITDA margins are expanding and the ₹7,100 crore, roughly 5,800-bed five-year capacity expansion is being funded through internal accruals rather than new borrowing, per management, with reported debt/equity near 0.85x. Not verified - check on Screener for the actual operating cash flow and free cash flow figures to confirm how much of this profit growth is converting to cash; that detail wasn't available from current sources. The nearer-term risk looks more operational than financial: new hospitals (Gurugram, Sonarpur, Financial District Hyderabad, Sarjapur) are running at a combined loss while ramping up, and the new NPPA margin cap on cancer drugs adds a fresh pressure point on the pharmacy/oncology revenue line.

Ownership

Promoter holding (the Reddy family, largely via PCR Investments Ltd) stands at 28.02% and has been stable. Promoter pledging has been cut sharply, from around 13% to about 2.49% of promoter holding, after a stake sale used to pay down debt - a meaningful reduction in that specific financial risk. Foreign institutional holding has risen to 43.18% from 41.49% in the prior quarter, while domestic institutional holding eased slightly to 22.07% from 24%, and mutual fund holding is roughly stable near 17%. No single marquee individual investor stands out on the shareholder register beyond routine institutional and promoter-family holdings.

The View

The one thing to watch

The actual listing of Apollo Healthtech (the merged AHLL + Apollo 24/7 + Keimed entity), expected in Q4 FY27 - its record date, share-swap ratio and standalone profitability will clarify how much of today's valuation belongs to the hospital business versus the digital/pharmacy business.

Strengths

  • +Q2 FY27 revenue up 23% YoY to ₹7,615 crore with EBITDA margin expanding to 15.64% from 14.93% - growth paired with margin gains, not one at the expense of the other
  • +Occupancy rose to 73% from 69% and operating beds grew 5.9% to 8,522, showing genuine demand-led volume growth rather than pricing alone
  • +Digital arm Apollo 24/7 turned cash-positive in Q2 FY27 versus a ₹39 crore loss a year earlier, and AHLL's EBITDA margin rose to 14.3% from 9.5% with PAT of ₹26 crore versus a ₹4 crore loss a year ago
  • +Promoter pledge cut from roughly 13% to about 2.49% of promoter holding, reducing a specific source of financial-stress risk

Watchpoints

  • !NPPA capped trade margins at 30% on 137 anti-cancer drug formulations effective November 9, 2026; oncology is roughly a fifth of revenue for large hospital chains, so this is a direct margin risk to watch in coming quarters
  • !The demerger of AHLL, Apollo 24/7 and Keimed into a separately listed entity has NCLT and shareholder approval but no confirmed record date or share-swap ratio yet, with management targeting a Q4 FY27 (Jan-Mar 2027) listing - this is still a pending event, not a completed one
  • !Newer hospitals (Gurugram, Sonarpur, Financial District Hyderabad, Sarjapur) posted a combined ~₹35 crore loss in Q2 FY27 while ramping up, and a further ₹7,100 crore, ~5,800-bed expansion is planned over five years
  • !The stock's 5-year return of 94.34% trails peer Max Healthcare's 176.94% by a wide margin, even though Apollo has outperformed over the more recent 1-year and 3-year periods

How sure are we about the data? · Moderate

Q2 and Q1 FY27 revenue, EBITDA, PAT and occupancy figures were cross-checked across multiple financial news sources and were consistent; minor rounding differences exist across sources for exact EBITDA (₹1,190-1,191 crore) and digital cash profit (₹1-1.3 crore) figures. The demerger timeline (NCLT order May 5, 2026; shareholder approval June 24, 2026; targeted Q4 FY27 listing) was corroborated by management's Nov 5, 2026 earnings call commentary. Not verified: exact free cash flow/operating cash flow conversion, the next quarter's results date, and the next dividend record date - none were confirmed from available sources, so check Screener or the company's exchange filings directly for these.

Keep it for later

Get the Apollo Hospitals Enterprise report as a PDF

The full report, neatly laid out with charts and tables, sent to your inbox. Handy to read offline or share.

Free. We use your email only to send this report and the newsletter.

Share this X LinkedIn WhatsApp

← All Nifty 100 companies

Reports are refreshed every quarter, about three days after each company announces its results.

Ticker Tales is not a SEBI-registered investment adviser or research analyst. This report is for learning only and is not investment advice. Data as of 6 Nov 2026.